XTSE
RVX
Market cap20mUSD
Oct 08, Last price
0.09CAD
1D
0.00%
1Q
-15.00%
Jan 2017
-95.00%
IPO
-96.37%
Name
Resverlogix Corp
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
5.19%
Rev. gr., 5y
%
Revenues
0
Net income
-8m
L+3.51%
CFO
-4m
L-4.14%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Resverlogix Corp. is an advanced-stage biotechnology company that focuses on developing therapies for medical conditions with significant unmet needs. The company's primary asset is apabetalone (RVX-208), a specialized small molecule bromodomain and extra-terminal inhibitor, which is currently undergoing Phase III clinical trials. This investigational treatment aims to address a spectrum of serious ailments, including cardiovascular disease, diabetes mellitus, chronic and end-stage kidney disease, and neurodegenerative disorders. Furthermore, Resverlogix has established a collaboration with Eversana Life Science Services, LLC. This alliance is geared towards supporting the forthcoming commercial introduction of apabetalone as a treatment for COVID-19 in both the United States and Canada. The company's operations are based out of Calgary, Canada.
Key people
Donald J. McCaffrey
Chairman of the Board, President, Chief Executive Officer, Secretary · since 2016
A. Brad Cann
Chief Financial Officer · since 2009
Jan O. Johansson
Senior Vice President - Medical Affairs · since 2004
Ewelina Kulikowski
Senior Vice President - Research and Development · since 2019
Kenneth Lebioda
Senior Vice President - Business Development · since 2006
Michael T. Sweeney
Senior Vice President - Clinical Development · since 2014
Shawn Lu
Director · since 2016
Director · since 2019
Kelly B. McNeill
Independent Director · since 2012
Eldon R. Smith
Lead Independent Director · since 2016
Headquarters & legal address
300, 4820 Richard Road SW
Calgary, AB T3E 6L1
CA
Calgary, AB T3E 6L1
CA
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2020‑04 | 2019‑04 | 2018‑04 | 2017‑04 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||